Peto's paradox: why whales and elephants rarely get cancer

What the phenomenon is

Cancer starts when a single cell accumulates enough mutations to divide out of control, so an animal with more cells, or more cell divisions over its lifetime, should statistically face a higher lifetime risk of the disease. Elephants have roughly 100 times as many cells as humans, and whales have far more still. By that logic, elephants and whales should be riddled with tumors well before old age. Instead, their measured cancer death rates are no higher than a mouse's, and often lower than a human's. The likely answer, researchers have found, lies in extra cancer-suppressing genes and unusually efficient DNA repair that evolved alongside their large bodies.

The popular claim

The idea gets repeated online as though whales and elephants were simply immune to cancer, a trait waiting to be bottled into a cure. That overstates the case. Peto's paradox is not a claim of immunity; it is a statistical mismatch between the cancer rate a simple cell-counting model predicts and the much lower rate that large, long-lived animals actually experience. Individual elephants and whales still get cancer. They just get it far less often than their cell counts would suggest.

Richard Peto's 1970s observation

The pattern is named for Richard Peto, a British statistician and epidemiologist. Writing in 1977, Peto pointed out that, across species, "there is not a strong correlation between cancer risk and body size," even though a straightforward model based on cell counts and lifespan predicts there should be one. Within a single species, bigger, older individuals do tend to carry somewhat higher cancer risk; across species, that relationship disappears.

The mismatch can be dramatic. Applying the equations that predict human colorectal cancer risk to a blue whale's body size implies that virtually all blue whales would develop that cancer by age 80. Mice, despite their short lives, have only about a one-to-four percent chance of the same cancer. Neither matches reality: whales are not dying en masse of colorectal cancer, and explaining that gap has driven decades of research.

Elephants' extra copies of a cancer-fighting gene

In October 2015, a team led by Lisa Abegglen and Joshua Schiffman at the University of Utah's Huntsman Cancer Institute, working with Arizona State University, published a study in JAMA. Analyzing a large database of elephant deaths, they estimated elephant cancer mortality at under 5 percent, compared with 11 to 25 percent in people, even though, in Schiffman's words, elephants "should be 100 times more likely to have a cell slip into a cancerous state."

The likely reason: elephants carry about 40 copies of the tumor-suppressor gene TP53, compared with two copies in humans. In response to DNA damage, the extra copies appear to push elephant cells toward apoptosis, a form of programmed self-destruction, more readily than human cells manage, eliminating damaged cells before a mutation can take hold.

A gene that came back from the dead

In August 2018, Vincent Lynch at the University of Chicago and colleagues reported in Cell Reports that elephants have a second layer of defense: a gene called LIF6, inactive for millions of years as a so-called pseudogene until a mutation in elephant ancestors switched it back on around 25 to 30 million years ago, roughly when those ancestors began growing to their present size.

When TP53 detects damaged DNA, it now switches LIF6 on. The LIF6 protein heads for a cell's mitochondria and pokes holes in them, killing the damaged cell before it can turn cancerous. Lynch's team put the toll of cancer at about 17 percent of humans worldwide, versus under 5 percent of captive elephants, despite elephants carrying roughly 100 times as many potentially cancerous cells and living some 70 years.

Bowhead whales: repairing DNA instead of destroying cells

Elephants are not the only long-lived giant that researchers have studied. Bowhead whales can live more than 200 years while carrying a whale-sized number of cells. Vera Gorbunova and Andrei Seluanov at the University of Rochester led research, published in Nature in October 2025, that found bowhead whale cells repair broken DNA strands faster and more accurately than the cells of other mammals do.

Much of that advantage traces to a protein called CIRBP, which bowhead whale cells produce at roughly 100 times the levels found in other mammals. Adding bowhead CIRBP to human cells in the lab improved their DNA repair, and adding it to fruit flies extended their lifespans. The researchers also found bowhead cells need fewer mutations than human cells to turn cancerous, but the whales' cells are "less likely to accumulate oncogenic hits in the first place."

Testing the pattern across the whole zoo

The broadest test of Peto's paradox itself, rather than of any one species' defenses, came from a study led by Orsolya Vincze and published in Nature in December 2021. The team built a database covering 110,148 zoo animals across 191 mammal species, drawing on postmortem records for 11,840 of them, and matched age-adjusted cancer mortality against each species' body mass and life expectancy.

Across the full dataset, body mass explained just 0.78 percent of the variation in cancer mortality risk between species, and life expectancy explained only 2.94 percent, which the authors called clear evidence for both the body-size and longevity halves of Peto's paradox. The same data turned up a pattern nobody had fully explained: carnivorous mammals, especially ones that eat other mammals, had the highest cancer mortality of any dietary group.

What is still debated

No single mechanism accounts for the whole pattern. Elephants lean on extra TP53 copies and a revived LIF6 gene; bowhead whales lean on faster DNA repair and a flood of CIRBP. Researchers have not settled on how many separate solutions evolution has produced across different mammal lineages, nor which of them, if any, could translate into treatments for human cancer.

The elevated cancer risk in carnivorous mammals that the 2021 zoo study found is also unexplained. It is not predicted by the basic cell-counting logic of Peto's paradox at all, and researchers have not yet confirmed why eating other mammals would raise cancer risk. The paradox describes a real, well-documented pattern; a complete account of why it holds, species by species, is still being assembled.

Verdict

Real or Legend has filed Peto's paradox itself as confirmed: decades of data, most recently the 2021 zoo study of more than 110,000 animals, show that cancer mortality does not rise with body size or lifespan across mammal species, in defiance of simple cell-counting math. What remains open is the full mechanism. Elephant and whale biology point to at least two distinct evolutionary solutions, extra tumor-suppressor genes in one case and enhanced DNA repair in the other, and researchers have not shown these explain every large, long-lived species or translate into a human treatment.